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Abstract
Background: The phenotypic heterogeneity of sickle cell disease is likely the result of multiple
genetic factors and their interaction with the sickle mutation. High transcranial doppler (TCD)
velocities define a subgroup of children with sickle cell disease who are at increased risk for
developing ischemic stroke. The genetic factors leading to the development of a high TCD velocity
(i.e. cerebrovascular disease) and ultimately to stroke are not well characterized.
Methods: We have designed a case-control association study to elucidate the role of genetic
polymorphisms as risk factors for cerebrovascular disease as measured by a high TCD velocity in
children with sickle cell disease. The study will consist of two parts: a candidate gene study and a
genomewide screen and will be performed in 230 cases and 400 controls. Cases will include 130
patients (TCD ≥ 200 cm/s) randomized in the Stroke Prevention Trial in Sickle Cell Anemia (STOP)
study as well as 100 other patients found to have high TCD in STOP II screening. Four hundred
sickle cell disease patients with a normal TCD velocity (TCD < 170 cm/s) will be controls. The
candidate gene study will involve the analysis of 28 genetic polymorphisms in 20 candidate genes.
The polymorphisms include mutations in coagulation factor genes (Factor V, Prothrombin,
Fibrinogen, Factor VII, Factor XIII, PAI-1), platelet activation/function (GpIIb/IIIa, GpIb IX-V, GpIa/
IIa), vascular reactivity (ACE), endothelial cell function (MTHFR, thrombomodulin, VCAM-1, E-
Selectin, L-Selectin, P-Selectin, ICAM-1), inflammation (TNFα), lipid metabolism (Apo A1, Apo E),
and cell adhesion (VCAM-1, E-Selectin, L-Selectin, P-Selectin, ICAM-1). We will perform a
genomewide screen of validated single nucleotide polymorphisms (SNPs) in pooled DNA samples
from 230 cases and 400 controls to study the possible association of additional polymorphisms with
the high-risk phenotype. High-throughput SNP genotyping will be performed through MALDI-TOF
technology using Sequenom's MassARRAY™ system.
Discussion: It is expected that this study will yield important information on genetic risk factors
for the cerebrovascular disease phenotype in sickle cell disease by clarifying the role of candidate
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genes in the development of high TCD. The genomewide screen for a large number of SNPs may
uncover the association of novel polymorphisms with cerebrovascular disease and stroke in sickle
cell disease.
Background
Sickle cell anemia (Hb SS) results from homozygosity for
a A→T substitution at codon 6 of the β-globin gene
(GAG→GTG) leading to a glutamic acid to valine
(Glu→Val) substitution in the β globin chain of human
adult hemoglobin. Despite this common genetic back-
ground, phenotypic expression of sickle cell disease is
widely variable, ranging from a mild, asymptomatic
course with survival into the sixth or seventh decade to a
very severe course with multi-organ damage and early
mortality [1]. Some of the genetic factors contributing to
this phenotypic diversity (particularly those linked to the
globin genes, i.e. α-thalassemia and β-globin gene cluster
haplotypes) have been well recognized [2].
Stroke is a devastating complication of sickle cell disease,
which occurs in 11% of the patients by 20 years of age as
shown by the multi-center Cooperative Study of Sickle
Cell Disease (CSSCD) [3,4]. In sickle cell patients <20
years of age, stroke is predominantly ischemic and results
from the involvement of medium sized to large intracra-
nial arteries. Ischemic stroke in the general population is
considered a multi-genic disorder [5,6]. In many cases it
results from multiple gene-gene and gene-environment
interactions. In the case of sickle cell disease, only a few
genetic factors are known to influence the stroke risk [7].
For example, α-thalassemia is the only well characterized
protective genetic factor [7]. Thus, genetic factors that lead
to the development of cerebrovascular disease and stroke
in children with Hb SS are not well understood.
Studies conducted at the Medical College of Georgia
(MCG) in the mid-1980's have shown that transcranial
doppler (TCD) can identify children at high risk for stroke
by detecting high flow rate in major intracranial arteries
[8,9]. Children with flow velocities of 200 cm/sec or
higher in middle cerebral or internal carotid arteries (nor-
mal = 140–170 cm/sec for sickle cell children) had a
stroke risk of 10–15% per year, which represents a 20-fold
increase over that for unselected children with sickle cell
disease. These observations then led to the multicenter
STOP (Stroke Prevention Trial in Sickle Cell Anemia)
study in which sickle cell children age 2–16 years, from 14
centers in the U.S. and Canada, were screened by TCD
[10]. One hundred thirty patients with flow velocities of
>200 cm/sec were randomized to observation or to
receive periodic blood transfusions to reduce % Hb S to
<30. The study was stopped early by the Data and Safety
Monitoring Board due to the finding of a significant
reduction in the number of strokes (90% reduction, p <
.001) in the transfusion arm (11 strokes in the observa-
tion arm vs. one in the transfusion arm) [11]. Thus, the
STOP study established that transfusion was an effective
means of primary stroke prevention in children with
sickle cell disease at risk for stroke as determined by TCD.
The recently funded STOP-II study, to be conducted in 24
centers, will investigate the duration of stroke risk and the
feasibility of discontinuing transfusion after 30 months in
patients whose TCD velocities have normalized after
transfusion.
Data from the STOP study showed that ~10% of patients
with Hb SS between the ages of 2–16 years are at risk for
stroke as determined by Transcranial Doppler (TCD)
velocities of 200 cm/sec or greater [11]. TCD velocity ele-
vation can be due to two factors: reduction of arterial
diameter due to stenosis and/or increased volume flow
through the artery. In the case of sickle cell disease, both
factors are often present. Velocity elevation corresponding
to increased cerebral blood flow in all patients with ane-
mia has been noted, with an approximate linear increase
in velocity for decrease in Hb or HCT [12]. There are also
data to suggest that patients with Hb SS have higher flow
velocities than those with normal Hb A at comparable lev-
els of anemia, suggesting the amount and composition of
the Hb are both involved in the velocity elevation of sickle
cell disease [13].
While some of the risk factors leading to the development
of cerebral vasculopathy and stroke in sickle cell disease
(low hematocrit, elevated white blood cell count, normal
complement of α-globin genes) have been identified in
previous studies (CSSCD, MCG cohort, and STOP), many
remain unknown. The observation has been made that
strokes in sickle cell disease are clustered in families, but
no clear epidemiological confirmation of this has been
published. In terms of TCD velocities, it was noted in the
STOP study that sibling pairs were common among
abnormals (i.e., TCD > 200 cm/sec) and there were 5 pairs
among 130 randomized patients suggesting that other
genetic factors may in part determine propensity for
stroke (RJ Adams, unpublished observations).
Various mechanisms have been proposed to account for
the "hypercoagulable state" observed in patients with
sickle cell disease. These include increased platelet activa-
tion, increased thrombin generation, and more recently,
elevated levels of circulating tissue factor [14]. Over theBMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/6
Page 3 of 10
(page number not for citation purposes)
past decade, mutations in a number of genes have been
identified as the cause of thrombophilia in a large number
of patients from different populations around the globe.
The molecular basis of inherited thrombophilia now
includes mutations in the genes for Factor V, pro-
thrombin, methylenetetrahydrofolate reductase (MTHFR)
and several others [15], in addition to those encoding pro-
teins such as antithrombin, protein C, and protein S
whose role in the homeostasis between procoagulant and
anticoagulant activities in the circulation is well estab-
lished. Unlike rare mutations involving antithrombin,
protein C and S, which are clearly associated with a hyper-
coagulable phenotype, mutations we propose to study
appear to have two distinct features: i) they occur with a
significantly higher frequency in many populations, and
ii) they seem to contribute to a thrombophilic state in the
presence of additional acquired (environmental/nutri-
tional) or inherited (interaction with other genes) factors.
It is likely that the co-inheritance of one or more of these
mutations in sickle cell disease would tip the balance
toward a hypercoagulable state and act as an additional
risk factor for the development of cerebrovascular disease.
Additionally, the effect of the thermolabile MTHFR muta-
tion (677 C→T) on plasma homocysteine levels in heter-
ozygotes has been shown to depend upon the availability
of folate, with higher levels seen in folate deficient indi-
viduals. It is possible that increased folate requirements
due to chronic hemolysis in sickle cell disease would lead
to a relative deficiency state, which, in the presence of
MTHFR mutation, would result in higher homocysteine
levels as an additional risk factor for vasculopathy.
Thus, we propose to study polymorphisms in genes
involved in a number of systems and pathways related to
stroke risk [5]: genes associated with coagulation factors
and thrombophilia (Factor V, Prothrombin, Fibrinogen,
Factor VII, Factor XIII, PAI-1, Thrombomodulin [TM], and
MTHFR), as well as polymorphisms in genes that are
involved in vascular reactivity (ACE), platelet activation/
function (GpIIb/IIIa, GpIb IX-V, and GpIa/IIa), endothe-
lial cell function (MTHFR, TM, VCAM-1, E-Selectin, L-
Selectin, P-Selectin, and ICAM-1), inflammation (TNFα),
lipid metabolism (Apo A1 and Apo E), and cell adhesion
(VCAM-1, E-Selectin, L-Selectin, P-Selectin, and ICAM-1).
These candidate genes will make it possible to study not
only polymorphisms associated with a hypercoagulable
state, but also to study the genes involved in pathways
that may lead to the development of vasculopathy (genes
involved in endothelial cell function, inflammation, and
adhesion, platelet activation and responsiveness). Thus,
this will provide the rationale for studying potential
genetic risk factors that may contribute to the pathogene-
sis of an "intermediate phenotype," such as vasculopathy
[5] rather than a thrombotic endpoint (i.e. stroke). TCD
remains the only proven indicator of cerebrovascular dis-
ease and stroke risk in Hb SS. Therefore, a large case-con-
trol association study of the role of genes in the
development of cerebrovascular disease and stroke risk
based upon TCD, is likely to provide more accurate infor-
mation and may resolve the controversial results obtained
in smaller studies [5]. Furthermore, an attempt will be
made to perform a subset analysis of patients who go on
to have an ischemic stroke during the study period in
terms of the associations with genetic polymorphisms. As
of the termination of the study in 2000, 18 of the 130
patients randomized in STOP have been adjudicated to
have a stroke.
In summary, we have designed a case-control association
study to elucidate the role of genetic polymorphisms as
risk factors for cerebrovascular disease, measured by a
high TCD velocity, in children with Hb SS. The study will
consist of two parts, a candidate gene study and a genom-
ewide screen and will be performed in 230 cases and 400
controls. Cases will include 130 patients randomized in
the STOP study (TCD ≥ 200 cm/s) as well as 100 patients
found to have high TCD in STOP II screening. Four hun-
dred sickle cell patients with a normal TCD velocity (TCD
< 170 cm/s) will be used as controls. The candidate gene
study will involve the analysis of 28 genetic polymor-
phisms in 20 candidate genes (see Table 1). References for
the polymorphisms listed in Table 1 are provided in the
additional file 1. The genomewide screen for a large
number of SNP markers may uncover the association of
novel polymorphisms with cerebrovascular disease and
stroke in sickle cell disease. DNA samples will be pooled
in the 230 cases and in the 400 controls and these pools
will be genotyped for a large number of validated SNPs
(we estimate to need at least 100,000 SNP markers) using
high-throughput methods. Purpose of this paper is to give
a detailed description of the design of this study.
Research Design and Methods
Subjects
African-American children who are between the ages of 2
and 16 years with Hb SS or Sβ0-thalassemia from partici-
pating STOP and STOP II centers form the subjects of this
study. The STOP study was conducted in 14 centers in
North American (13 US and 1 Canadian). STOP II is being
conducted in 28 centers (27 US and 1 Canadian). Banked
DNA samples from randomized STOP patients (n = 130)
stored in the STOP Core Laboratory will be utilized. An
additional 100 patients with high TCD velocity and 400
control patients with normal TCD velocity will be identi-
fied through STOP-II screening. With an abnormal TCD
rate of 10%, it is expected that at least 1000–1400 new
patients from 24 participating Centers will need to be
screened as part of the STOP-II study to identify 100 new
patients with TCD velocities >200 cm/sec. DNA will beBMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/6
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extracted from the 5 ml blood collected in EDTA and
shipped to the Core Laboratory, collected during TCD
screening as part of STOP-II.
Cases and controls will be matched for age, sex, and
weight, which are the most important covariates. The
effect of any remaining differences in additional con-
founding variables between cases and controls will be
explored by adjusting for these covariates in the analyses,
for example through using conditional logistic regression
models.
Human Biological Materials
To ensure confidentiality and protect the privacy of sub-
jects they will not be identified by name, acrostics will be
used. Authorized officials from the state and federal gov-
ernments and authorized representatives of the Medical
College of Georgia will have access to confidential data,
which will identify the patients. Patients will not be iden-
tified in any reports or publications resulting from this
study. Banked STOP DNA samples were anonymized
according to a plan approved by the Institutional Review
Boards of the Medical College of Georgia and the New
England Research Institute. Informed consent was
obtained for subjects screened as part of the STOP II study.
In accordance with the National Bioethics Advisory Com-
mission Recommendations [16] subjects and their physi-
cians will not be notified of the test results unless all three
of the following conditions are met:
1) The findings are scientifically valid and are confirmed
2) The findings have significant implications for the sub-
ject's health concerns
3) A course of action to treat these concerns is readily
available
SNP Genotyping
DNA will be extracted from peripheral blood mononu-
clear cells and 5 µg of genomic DNA from each subject
will be used for each multiplex SNP genotyping assay (the
STOP DNA bank has 66–1740 µg of DNA from rand-
omized patients). The 28 polymorphisms in 20 candidate
genes and the SNP markers in the genomewide screen will
be genotyped by high-throughput SNP screening using
the MassARRAY™ System (Sequenom Inc., San Diego,
CA). The principles of this method are detailed in refer-
ences [17] and [18]. Briefly, approximately 300 bp frag-
ments of each candidate gene, with the SNP site in the
middle, will be amplified by automated PCR procedure.
Multiplexing of the PCR reactions will be used as
determined by the Sequenom software. One of the ampli-
fication primers includes a 5' biotin tag, which is targeted
in a streptavidin-magnetic bead purification step to gener-
ate a single stranded template for the primer extension
reaction. An extension primer complimentary to the tem-
plate at a region directly adjacent to the SNP site is added
to the single stranded template. This is followed by the
MassEXTEND™ reaction during which the primer is
extended across the SNP site by using a sequencing
polymerase reaction. This is controlled by a mixture of
dideoxy and deoxy nucleotide triphosphates, the ratio of
which varies depending upon the assay design protocol
obtained from the SpectroDESIGNER™ software (Seque-
nom). The primer extension products will differ depend-
ing upon the polymorphic base present at the SNP site.
The difference in molecular weight between these prod-
ucts is detectable by mass spectrometry. Following the
Table 1: List of 28 polymorphisms in 20 candidate genes used in this study
GENE POLYMORPHISM REFERENCE GENE POLYMORPHISM REFERENCE
1 Factor V R506Q 
(LeidenG1691A)
4 15 GpIIb/IIIa Leu33Pro (PLA2) 16
2 Factor V R485K (A1628G) 5 16 GpIb IX-V: GpIbα 
VNTR
(D,C,B,A):C/B 17
3 Factor V HR2 (His1299Arg) 6 17 GpIa/IIa:α2 gene nt 807 C/T 18
4 Factor V HR3 (His1254Arg) 1 18 TNFα: 308 G/A 19
5 Prothrombin 20210G/A 4 19 Apo A1 C93T: G121A 20
6 MTHFR C677T 7,8 20 Apo E Cys112Arg 21
7 ACE I/D 2,3 21 VCAM-1 G1385C 22
8 Fibrinogen – Beta chain 455 G/A 9 22 E-Selectin G98T 23
9 Fibrinogen – Beta chain 148 C/T 10 23 E-Selectin C1839T L554F 23
10 Factor VII R353Q (Arg353Gln) 11 24 E-Selectin A561C S128R 24
11 FactorXIII Val34Leu 12 25 L-Selectin C188G T49S 24
12 TM Ala455Val:C/T 13 26 L-Selectin T668C F206L 25
13 TM A25Thr:G/A 14 27 P-Selectin C715A 26
14 PAI-1 675 4G/5G 15 28 ICAM-I G778A G214R 23
Note: MTHFR, Methylenetetrahydrofolate reductase; ACE, Angiotensin converting enzyme; TM, Thrombomodulin; PAI-1, Plasminogen activator 
inhibitor-1; Gp, platelet glycoprotein; TNFα, Tumor necrosis factor α; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion 
molecule 1BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/6
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extension reaction, the original sample template is sepa-
rated and removed from the extended primers by the use
of a resin. The purified samples are then transferred onto
a SpectroCHIP™ (from either a 96 well or 384 well plate)
with the SpectroJET™ dispenser. The CHIP is placed into
the mass spectrometer, which takes advantage of the
MALDI-TOF (Matrix Assisted Laser Desorption/Ionization
Time-of-Flight) mass spectrometry. The mixture of the test
molecules (extension products) with the organic matrix
produces a crystalline dispersion. The matrix is hit with a
pulse from a laser beam. The sample and matrix are vapor-
ized and the primer extension products are expelled into
the flight tube. As the primer extension products are neg-
atively charged when an electrical field pulse is subse-
quently applied, they are launched down the flight tube
toward the detector. The time between application of the
electrical field pulse and collision of the primer extension
products with the detector is known as "time-of-flight"
and is a very precise measure of the product's molecular
weight. The SpectroTYPER™ software gathers the time-of-
flight information and applies algorithms to provide accu-
rate, automated genotype calling. This method is fast and
more accurate compared to hybridization-based methods
of SNP detection [17,18]. The whole process is
automated.
Data Management
Web-based data entry will be used to load the data from
this study into the password-protected STOP II database at
the New England Research Institutes (NERI). A data entry
screen specific to this study will be developed for this pur-
pose. Adding the data to the STOP II database will greatly
facilitate linking the genotyping data to other patient
characteristics (e.g. TCD status) during data analysis. The
database was developed using NERI's browser-based data
management system, ADEPT, and an ORACLE relational
database engine. As part of standard QC, 10% of the
records will be randomly selected at NERI for double data
entry. Any problems with high error rates will be brought
to the attention of laboratory personnel immediately. If
necessary, further records entered by the same individual
will also be reviewed.
Statistical analysis for the candidate gene study
As a first step in the analysis, the genotypic frequencies for
each gene will be tested for departure from Hardy-Wein-
berg equilibrium. Statistically significant departures could
indicate biased sampling or they could indicate that the
study population is experiencing detectably strong natural
selection at that locus.
The null hypothesis to be tested for each gene is that the
genotypic frequencies in patients with normal and high
TCD are the same. This will be tested using a chi-square
test of association of TCD status and genotype for each
gene. Heterozygotes will be pooled with homozygous
mutants to form 2 × 2 tables (mutant present/absent vs.
TCD status). Fisher's exact test will be used instead of chi-
square tests if the frequency of a given allele is too low to
justify the assumptions of the chi-square test. Rejection of
the null hypothesis of no association between genotype
and TCD status will lead to the conclusion that the pro-
portion of patients with mutant alleles is different in
patients with normal and high TCD. The Bonferroni cor-
rection for multiple testing will not be used because cor-
recting for tests at 20 loci would produce an extremely
small critical p-value. In the absence of such a correction,
the results of this study will need to be considered with
caution and replication of significant findings in an inde-
pendent sample or follow-up study will be important.
A multivariate approach will then be employed to deter-
mine if TCD status varies with combinations of different
genes; i.e. to determine if the probability that a patient
with mutant alleles for two or more genes is a case (i.e. has
high TCD) differs from the probability that is predicted
from the independent effects of those genes. Loglinear
models will be employed for this [19]. Suppose, for exam-
ple, that the data from two genes are combined with TCD
status to form a 2 × 2 × 2 table. Rejection of the null
hypothesis of no three-way association in the table would
lead to the conclusion that the proportion with high TCD
depends upon the joint effects of the two genes rather
than on their separate effects. The cell frequencies in the
table would then be inspected to determine which combi-
nations of alleles accounted for the statistically significant
results; i.e. to identify the combinations that occur with
elevated frequency in patients with high TCD. Bishop et
al. [19] provide methods for calculating standard errors
for the cell frequencies for this inspection.
Generally, statistical tests of three-way and higher order
associations are less powerful than tests of two-way
associations in the same table. More specific statements
regarding power are difficult without explicit statements
regarding the magnitude of interaction to be detected and
there is very little information available on which to base
the latter. Therefore, the analysis of individual genes
should be considered the primary analysis in this study.
Interactions involving more than three or four variables
are generally very difficult to interpret. Therefore, the anal-
ysis will be limited to tables involving no more than two
or three genes. Even that restriction is unlikely to be suffi-
cient, given the large number of tables involving either
two or three genes that could be formed from the data.
Therefore, multivariate modeling will begin with any
genes that were statistically significantly related to TCD
status when the data for each gene were analyzed
separately.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/6
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Power estimates for the candidate gene study
In the calculations below, heterogyzotes are pooled with
homozygous mutants to reduce each population to two
states (mutant present or absent). The power to detect a
difference in genotypic frequencies between two popula-
tions was determined by Monte Carlo simulation. The
simulations were based on three assumptions: (i) only
two alleles are involved in the comparison for a given
gene; (ii) the populations are in Hardy-Weinberg equilib-
rium; and (iii) genotypes will be obtained from 230 cases
and 400 controls. The simulations proceeded as follows.
1. Specify the proportion of homozygous mutants in each
population (p1 for cases and p2 for controls). The propor-
tions of homozygous wild type and heterozygous patients
in the ith population are then (1 - pi
1/2)2 and 2pi
1/2(1 - pi
1/
2) respectively.
2. Draw random samples of size 230 and 400 from the
two multinomial populations defined above. Pool the
heterozygotes and homozygous mutants to reduce each
population to two states (mutant present/absent).
3. Compare the genotypic frequencies in the two samples
using a chi-square test.
4. Repeat steps 2–3 5,000 times for each combination of
p1 and p2. Estimate statistical power as the percentage of
simulations in which the null hypothesis was rejected.
Results are presented in table 2. On the assumption that
the goal of the study is to identify mutant alleles that occur
with increased frequency in patients with high TCD, the
table is limited to cases in which p1 > p2. To save space, the
table is further limited to entries that just span the range
of differences, p1 - p2, that can be detected with 80–90%
power for each specified value of p1. Based on these power
analyses we conclude that we have good power to detect
realistic differences in frequencies of alleles that increase
risk of cerebrovascular disease and stroke in cases as com-
pared to controls.
Design of DNA pooling for genomewide association screen
DNA pooling is a practical way to reduce the cost of large-
scale case-control association studies, because it allows
measurement of allele frequencies in groups (or pools) of
individuals, thereby reducing the number of PCR reac-
tions and genotyping assays dramatically. Primer exten-
sion is the technique that has been most commonly used
in pooling studies to genotype SNPs and the results have
been very good [20]. Resolution of allele frequency differ-
Table 2: Power to detect the difference between the genotypic distributions in two populations, assuming a sample of 230 from 
population 1 (cases) and 400 from population 2 (controls).
P1 P2 P1-P2 POWER
0.030 0.010 0.020 0.95
0.009 0.021 0.97
0.008 0.022 0.99
0.007 0.023 0.99
0.050 0.025 0.025 0.77
0.023 0.027 0.85
0.021 0.029 0.92
0.020 0.030 0.94
0.100 0.057 0.043 0.78
0.055 0.045 0.82
0.050 0.050 0.91
0.200 0.130 0.070 0.74
0.120 0.080 0.86
0.110 0.090 0.94
0.100 0.100 0.98
0.300 0.200 0.100 0.80
0.190 0.110 0.88
0.180 0.120 0.94
0.400 0.280 0.120 0.79
0.270 0.130 0.84
0.250 0.150 0.94
0.500 0.360 0.140 0.77
0.350 0.150 0.84
0.330 0.170 0.93
Note: P1, the proportion of homozygous mutants in population 1; P2, the proportion of homozygous mutants in population 2.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/6
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ences between cases and controls in pooling studies is
limited, however, by so called pool-measurement and
pool-formation errors. Differential amplification of differ-
ent SNPs during PCR and the limited accuracy of the
detection method lead to pool-measurement errors. For
example, allele frequency estimates of pools using
MALDI-TOF mass spectroscopy have been reported to
deviate from real by approximately 3% [21]. Another
source of error is caused by unequal amount of DNA
being contributed by individuals that make up the pool
(pool-formation errors). In principle the power of pool-
ing studies can be improved by creating multiple pools
from the same individuals (reducing pool-formation
errors) and multiple measurement of allele frequencies
(reducing the pool-measurement error). However, for our
study we propose to follow the recommendations as
recently outlined by Sham et al [20]. They state that a two-
stage design, in which markers showing positive associa-
tion in a pooling study are followed up by confirmatory
individual genotyping, might represent the best trade-off
between the cost savings of pooling and the full informa-
tion provided by individual genotyping. We propose to
test the full marker set of 100,000 SNPs in the genome
screen using pooled assays with a relatively liberal p-value
(e.g. 0.01–0.001) to allow adequate power even with
information loss. Markers that show significance in the
pooled assay will then be genotyped in all individuals of
the original case-control sample to confirm the
association.
Discussion
Identifying genes for polygenic ischemic stroke has been a
difficult task and most human studies have employed a
candidate gene approach [5] although at least one genom-
ewide linkage scan in affected sibling pairs is on the way
[22]. We propose to use a combination of a candidate
gene association study and genomewide association scan
in children with Hb SS at high (230 cases) or low (400
controls) risk for cerebrovascular disease as determined by
their TCD velocity.
Association studies of candidate genes for complex dis-
eases have been criticized because of non-replication of
results [23] and studies of genetic risk factors in ischemic
stroke have been no exception [5,22]. Rish [24] has
argued that the most likely reason for the high false-posi-
tive rate is the low prior probability in most candidate
gene studies that the examined polymorphisms are caus-
ally related to the disease outcome. All 28 polymorphisms
in 20 candidate genes that we propose to study have been
shown to be associated with a hypercoagulable state or
have been shown to be involved in pathways leading to
the development of vasculopathy and, therefore, have a
high probability to be related to the TCD velocity
phenotype.
One of the causes for conflicting results in candidate gene
studies and in particular for spurious associations is
believed to be population stratification or admixture [25].
Population stratification refers to the presence of sub-
groups, e.g. ethnic groups, in the sample and can poten-
tially cause a spurious association between the locus and
trait. A spurious association due to population stratifica-
tion can only occur when two conditions hold: (i) the
population strata differ with respect to the phenotype,
and (ii) the population strata differ in allele frequencies.
Although population stratification is frequently used as
an explanation for non-replicable associations in the liter-
ature, there are few actual examples to support this
assumption [24] and experts in the field now agree that
the problem has probably been overstated [25]. For
example, Wacholder et al. [26] argue that population
stratification of an extent large enough to distort results is
unlikely to occur in many realistic situations. Ardlie et al.
[27] evaluated 4 moderately sized case-control studies for
the presence of population structure and concluded that
carefully matched case-control samples in cosmopolitan
US and European populations are unlikely to contain lev-
els of population stratification that would result in signif-
icantly inflated numbers of false positive associations. We
therefore believe that hidden stratification is unlikely to
be a problem in our case-control study of African-Ameri-
can children with sickle cell disease at high or low risk for
cerebrovascular disease based on their TCD values. How-
ever, methods are being developed by which unlinked
genetic markers can be used to detect stratification and
even correct for it when it is present [28,29]. In the
unlikely event of spurious association results, we will be
able to use these methods to detect and adjust for the
effect of the population stratification present. Further-
more, the study of other genetic markers, namely the dis-
tribution of β-globin haplotypes and the frequency of
deletional  α-thalassemia among African-American
patients with sickle cell disease from different centers in
the United States do not show significant differences argu-
ing against significant population admixture in this group
[4,11,30,31].
Our genomewide association scan aimed at identifying
novel polymorphisms associated with stroke risk will nec-
essarily have a somewhat exploratory character. The rea-
son is simply that this approach has only recently become
possible with the advent of high throughput SNP geno-
typing and we are not currently aware of any published
studies that have used genomewide association for identi-
fication of susceptibility loci of complex traits. Two issues
are worth discussing at this point: (i) the optimization of
selection criteria for the case and control pools and (ii) the
total number of SNP markers needed to provide adequate
coverage of the whole genome.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/6
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Our definition of cases and controls in this study is based
on absolute cut-off values for TCD velocity. For quantita-
tive traits like TCD velocity, loss of efficiency in a pooling
design is due to loss of information from within-pool
phenotypic differences. In the absence of experimental
errors, this information loss can be minimized by opti-
mizing the criteria for selection of individuals from the
extreme tails of the distribution for the two pools, which
turns out to be the upper and lower 27% of this distribu-
tion [20]. Interestingly, this optimal pooling fraction is
largely independent of marker frequency and mode of
inheritance of the trait. Exploration of alternative selec-
tion criteria for cases and controls in our genomewide
association study will be dependent on the combined
TCD distribution of the 1000 to1400 new patients that
will be screened as part of the STOP-II study and the 130
patients (TCD ≥ 200 cm/s) from the original STOP study
that are already available.
The number of SNPs that are required for whole-genome
linkage disequilibrium (LD) mapping has been a hotly
debated issue in the last few years. Initial simulation esti-
mates based on monotonic population expansion sug-
gested that useful LD was unlikely to extend beyond 3 kb,
implying a number of 500,000 SNPs necessary for a
whole-genome scan [32]. Another study looking at real
data found that LD extended over much larger distances
and arrived at an estimate as small as 30,000 SNPs, or 1
SNP per 100 kb [33]. Recent evidence suggests that the
genome consists of blocks of high LD (haplotype blocks)
separated by recombination hot spots [34]. Within each
block, a limited number of common haplotypes (three to
five) typically capture about 90% of all chromosomes,
which means that a reduced number of SNPs would be
needed to characterize these haplotypes [35]. Thus, the
recently initiated construction of a haplotype map of the
human genome may facilitate selection of SNP markers
for genomewide association studies like ours. In the
meantime, replication of significant associations detected
in the candidate gene part of the study with our genom-
ewide approach should provide us with practical esti-
mates for the likely density of SNP markers needed for
successful LD mapping.
The practical and clinical implications of potential find-
ings of this study remain unclear. The association of one
or more polymorphisms in the candidate genes with a
high TCD (high risk) phenotype will enable the investiga-
tors to streamline the screening and follow-up programs
towards those with high risk as determined by genetic test-
ing. The incorporation of any preventive or therapeutic
measures into this program will depend not only on the
findings of association of high TCD phenotype with cer-
tain SNPs but also on the results of the ongoing STOP II
study, which is studying the optimal duration of transfu-
sion in these high risk children.
In conclusion, we believe that our dual approach of a can-
didate gene and whole-genome association study will
yield important information on genetic risk factors for cer-
ebrovascular disease in sickle cell disease. Not only will
this generate important knowledge for improving treat-
ment and prevention options of patients with Hb SS, pol-
ymorphisms showing a significant association will also be
strong candidates for stroke risk in the general popula-
tion. Such associations can efficiently be confirmed in
banked DNA of large cohorts of stroke cases and controls
[22].
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